Contributions
Abstract: EP1343
Type: ePoster
Abstract Category: Clinical aspects of MS - 5 Epidemiology
Objectives: Comorbidity is an area of increasing interest in multiple sclerosis (MS) and may have adverse impacts on MS course causing greater disability progression and influencing treatment choices and treatment outcomes. Our aims were to characterize the comorbidites of the MS center of Bergamo.
Materials and methods: We retrospectively evaluated the clinical history of 601 consecutive patients afferent to our MS center in 2016. We reported all comorbidities which could be relevant to health care utilization and could influence treatment choices in MS patients.
Results: Overall we evaluated the data of 487 patients with relapsing remitting MS, 103 patient with secondary progressive MS and 11 patients with primary progressive MS. 67% of our cohort were females and 33% were males. Mean age was 43.9 years old (SD 11.7). Median EDSS was 2.0 (range 1.0-9.0). 42.2% of patients had at least one comorbidity (28.2% only one comorbity, 14.0% two or more comorbidities). Overall, at least one comorbidity was already present at diagnosis in 8.8% of our sample; 33.4% of subjects developed at least one comorbidity during MS disease course. 9.8% of our patients were affected by hypertension, 5.8 % by dyslipidemia, 2.3% by diabetes, 2.8% by cardiac diseases, 4.7% by malignant tumors (21.4% breast cancer, 25.0% genito-urinary tumors, 7.1% gastrointestinal tumors, 3.6% lung cancer, 32.1% skin cancers, 10.8% other tumors), 20% by psychiatric disorders ( 86.6 % anxiety-depressive disorder, 13.4% psychosis or bipolar disorder) and 9.7% by autoimmune diseases (64,7% autoimmune thyroiditis, 9.8% psoriasis, 7,8% celiac disease, 17,7% other mixed autoimmune diseases). Diabetes and autoimmune disorders were equally detected before and after MS diagnosis, while the remaining comorbidities onset was more frequent during MS disease course.
Discussion and conclusions: We reviewed the prevalence of comorbidities in a single MS center. The high prevalence of comorbidities in our cohort underlines the complexity of MS patients, which is not confined to MS direct complications. A high rate of subjects developed comorbidities after diagnosis. An adequate prevention and a prompt management of comorbidities during MS disease course is essential and might be the key to ameliorate the health care utilization, prevent serious adverse events during MS treatment and obtain better clinical outcomes.
Disclosure: Zanchi: nothing to disclose
La Gioia: nothing to disclose
Barcella: nothing to disclose
Gardinetti: nothing to disclose
Conti: nothing to disclose
Frigeni: nothing to disclose
Vedovello nothing to disclose
Rottoli nothing to disclose'
Abstract: EP1343
Type: ePoster
Abstract Category: Clinical aspects of MS - 5 Epidemiology
Objectives: Comorbidity is an area of increasing interest in multiple sclerosis (MS) and may have adverse impacts on MS course causing greater disability progression and influencing treatment choices and treatment outcomes. Our aims were to characterize the comorbidites of the MS center of Bergamo.
Materials and methods: We retrospectively evaluated the clinical history of 601 consecutive patients afferent to our MS center in 2016. We reported all comorbidities which could be relevant to health care utilization and could influence treatment choices in MS patients.
Results: Overall we evaluated the data of 487 patients with relapsing remitting MS, 103 patient with secondary progressive MS and 11 patients with primary progressive MS. 67% of our cohort were females and 33% were males. Mean age was 43.9 years old (SD 11.7). Median EDSS was 2.0 (range 1.0-9.0). 42.2% of patients had at least one comorbidity (28.2% only one comorbity, 14.0% two or more comorbidities). Overall, at least one comorbidity was already present at diagnosis in 8.8% of our sample; 33.4% of subjects developed at least one comorbidity during MS disease course. 9.8% of our patients were affected by hypertension, 5.8 % by dyslipidemia, 2.3% by diabetes, 2.8% by cardiac diseases, 4.7% by malignant tumors (21.4% breast cancer, 25.0% genito-urinary tumors, 7.1% gastrointestinal tumors, 3.6% lung cancer, 32.1% skin cancers, 10.8% other tumors), 20% by psychiatric disorders ( 86.6 % anxiety-depressive disorder, 13.4% psychosis or bipolar disorder) and 9.7% by autoimmune diseases (64,7% autoimmune thyroiditis, 9.8% psoriasis, 7,8% celiac disease, 17,7% other mixed autoimmune diseases). Diabetes and autoimmune disorders were equally detected before and after MS diagnosis, while the remaining comorbidities onset was more frequent during MS disease course.
Discussion and conclusions: We reviewed the prevalence of comorbidities in a single MS center. The high prevalence of comorbidities in our cohort underlines the complexity of MS patients, which is not confined to MS direct complications. A high rate of subjects developed comorbidities after diagnosis. An adequate prevention and a prompt management of comorbidities during MS disease course is essential and might be the key to ameliorate the health care utilization, prevent serious adverse events during MS treatment and obtain better clinical outcomes.
Disclosure: Zanchi: nothing to disclose
La Gioia: nothing to disclose
Barcella: nothing to disclose
Gardinetti: nothing to disclose
Conti: nothing to disclose
Frigeni: nothing to disclose
Vedovello nothing to disclose
Rottoli nothing to disclose'